

Amendments to the Claims:

Following is a complete listing of the claims pending in the application, as amended:

1. (Currently amended) A δ V1-1 peptide comprising an amino acid sequence that has at least 50% identity with identified as SEQ ID NO:4 and activity as an antagonist of δ PKC ~~and derivatives and fragments thereof.~~

2. (Currently Amended) The peptide of claim 1 ~~wherein the derivative is selected from the group consisting of δ V1-1 derivatives identified as SEQ ID NOS:34-48.~~

Claims 3-4 (Canceled)

5. (Currently amended) The peptide of claim 1, ~~wherein the fragment has the sequence selected from the group identified as SEQ ID NOS:49-[64]~~ 50.

6. (Canceled)

7. (Original) The peptide according to claim 1, wherein said peptide is recombinantly produced.

8. (Original) The peptide of claim 1, wherein the peptide is chemically synthesized.

9. (Original) The peptide of claim 1, wherein the peptide is encoded by a polynucleotide.

Claims 10-58 (Canceled)

59. (New) The peptide of claim 1 comprising an amino acid sequence that has at least 70% identity with SEQ ID NO:4.

60. (New) The peptide of claim 1 comprising an amino acid sequence that has at least 80% identity with SEQ ID NO:4.

61. (New) The peptide of claim 1 having a terminal cysteine.

62. (New) The peptide of claim 2 having a terminal cysteine.

63. (New) The peptide of claim 5 having a terminal cysteine.

64. (New) The peptide of claim 1 consisting essentially of SEQ ID NO:4.

65. (New) The peptide of claim 64 having a terminal cysteine.

66. (New) A δ V1-1 peptide consisting essentially of SEQ ID NO:4 and having activity as an antagonist of δ PKC.

67. (New) The peptide of claim 66 having a terminal cysteine.

68. (New) A peptide consisting essentially of SEQ ID NO:4.

69. (New) The peptide of claim 68 having a terminal cysteine.

70. (New) A peptide consisting of SEQ ID NO:4.